Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.47 |
| ▸ | SPR | P35270 | 3/20 | 0.46 |
| ▸ | RBP4 | P02753 | 2/20 | 0.46 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.45 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.45 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12761089 | 0.83 | L3MBTL1 (0.57) | L3MBTL1SMN1; SMN2RBP4 | |
| SCHEMBL1088005 | 0.83 | L3MBTL1 (0.69) | L3MBTL1GPR119POLBRBP4KDR | |
| SCHEMBL1102308 | 0.82 | SETD7 (0.65) | SETD7L3MBTL1GPR119USP30SPR | |
| SCHEMBL3638878 | 0.82 | SETD7 (0.65) | SETD7L3MBTL1GPR119USP30SPR | |
| SCHEMBL26814604 | 0.80 | L3MBTL1 (0.54) | L3MBTL1SMN1; SMN2RBP4 | |
| SCHEMBL31155296 | 0.80 | SETD7 (0.52) | SETD7L3MBTL1GPR119SPRSMARCA2 | |
| SCHEMBL26669286 | 0.80 | SETD7 (0.52) | SETD7GPR119SPRSMARCA2SMARCA4 | |
| SCHEMBL20129601 | 0.79 | GPR119 (0.60) | GPR119POLBSMARCA2SMARCA4PBRM1 | |
| SCHEMBL20129618 | 0.79 | GPR119 (0.60) | GPR119POLBSMARCA2SMARCA4PBRM1 | |
| SCHEMBL20142792 | 0.79 | GPR119 (0.60) | GPR119POLBSMARCA2SMARCA4PBRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368133-A1 | Compounds for the Treatment of Pain, in Particular, Neuropathic Pain, and/or Other Diseases or Disorders that are Associated with AT2R and/or AT2R Mediated Signaling | CONFO THERAPEUTICS N.V. (BE) | 2024-11-07 | — | — | US | disclosed |
| CN-118159530-A | Compounds for the treatment of pain, in particular neuropathic pain and/or other diseases or disorders associated with AT2R and/or AT2R mediated signalling | 康福治疗有限公司 | 2024-06-07 | — | — | CN | disclosed |
| US-20110130379-A1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | Convergence Pharmaceuticals Limited (GB) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368133-A1 | Compounds for the Treatment of Pain, in Particular, Neuropathic Pain, and/or Other Diseases or Disorders that are Associated with AT2R and/or AT2R Mediated Signaling | AGTR2, AGTR1, OPRL1 | SETD7 4834/4885L3MBTL1 3960/4885GPR119 225/4885 |
| US-20110130379-A1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | CACNA1B, CACNA1C, CACNB2 | SETD7 3948/4885L3MBTL1 4629/4885GPR119 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.